This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Abstract Details

Activity Number: 583
Type: Contributed
Date/Time: Wednesday, August 4, 2010 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract - #307699
Title: Exponential Failure-Time Mixture Model for Evaluating Efficacy in the Presence of a Biomarker: KRAS Validation
Author(s): Kallappa M. Koti*+
Companies: FDA
Address: 10903 New Hampshire Avenue, Silver Spring, MD, 20993-0002,
Keywords: AFT model ; mixture proportion ; likelihood ratio test ; interaction ; ITT analysis ; identifiability

PFS results from the Amgen Study 20020408 were presented and discussed in the December 2008 Oncologic Drugs Advisory Committee. Using the retrospective subgroup analyses it was claimed that KRAS status should be considered when selecting mCRC patients as candidates for panitumumab monotherapy. Similar conclusion was made by Amado et al. (2008). Results based on retrospective "sorted" analyses are not conclusive. We propose an exponential failure-time mixture model that helps to both validate a marker and demonstrate drug efficacy. The model facilitates a comparison of PFS between the wild-type and mutant KRAS subgroups of subjects on the panitumumab arm. The objective of this presentation is to provide details and to discuss the scope and limitation of the proposed methodology. The views expressed here do not necessarily reflect those of the Food and Drug Administration.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2010 program

2010 JSM Online Program Home

For information, contact or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.